Intrathecal Methotrexate: A Treatment Option for Patients With Progressive Multiple Sclerosis?
Could intrathecally administered methotrexate be a viable treatment option for your patients with progressive forms of multiple sclerosis?
Could intrathecally administered methotrexate be a viable treatment option for your patients with progressive forms of multiple sclerosis?
Here to discuss the results of a study designed to test the feasibility of this therapeutic approach is neurologist Saud Sadiq. Dr Sadiq is Founder and Director of the International Multiple Sclerosis Management Practice and the Multiple Sclerosis Research Center of New York.
Dr Sadiq and his coauthors published their study in the Journal of Neurology. For the full report, please click here [pdf].
Intrathecal Methotrexate for Patients With MS?
FDA Accepts Protocol for Annovis Bio’s Buntanetap Phase 3 Alzheimer Disease Trial
January 9th 2025Buntanetap is an oral molecule designed to inhibit the production of multiple neurotoxic proteins and is under investigation for treatment of Alzheimer Disease, Parkinson’s Disease, and other neurodegenerative diseases.
